

63. The method of claim 36, wherein in step (b) said target diseased cell is treated by incubating said target diseased cell with one or more cytokines capable of increasing the levels of one or more primary and costimulatory T cell activation molecules in said target diseased cell.
64. The composition of claim 1, wherein said target diseased cell is transferred with a gene encoding a primary T cell activation molecule or a costimulatory T cell activation molecule.
65. The composition of claim 1, wherein said target diseased cell is transferred with a gene selected from the group consisting of MHC genes, adhesion molecule genes, and cytokine genes.

**REMARKS**

Applicant thanks the Examiner for granting a telephonic interview on November 10, 1998.

Applicant acknowledges that the Examiner withdrew rejection of claims 1-22 and 33-51 under 35 U.S.C. § 112, first paragraph in the Final Office Action dated October 13, 1998.

Applicant also acknowledges that the Examiner withdrew rejection of claims 1-22 and 33-51 under 35 U.S.C. § 103(a) in the Examiner's Interview Summary of November 10, 1998. In the same interview summary, the Examiner withdrew the finality of the last office action and encouraged Applicant to suggest the next species for examination.

In that regard, Applicant suggests expanding the examination to cover bridge molecules comprising a binding site for 4-1BB on the surface of T cells and submits new claims 52-65. Claims 1-22 and 33-65 are pending in this application. Claim 52 relates to claim 1. Claim 53 relates to claim 21. Claim 54 relates to claim 18. Claim 55 relates to claim 16. Claim 56 relates to claim 48.

Claim 57 relates to claim 36. Claims 58-63 are dependent on claim 36. Claims 64 and 65 are dependent on claim 1. Applicant submits that no new matter is introduced by the amendment and the new claims are fully supported by the specification, including, but not limited to, pages 2-20 of the specification.

Accordingly, Applicant submits that claims 1-22 and 33-65 are now in condition for allowance and a notice to that effect is respectfully requested. If there is any fee due in connection with this response, please charge Deposit Account No. 12-2475 for the appropriate amount.

Respectfully submitted,

LYON & LYON LLP

Dated: Nov. 18, 1998

By:

  
Anthony C. Chen -  
Reg. No. 38,673

Lyon & Lyon LLP  
633 West Fifth Street, Suite 4700  
Los Angeles, California 90071-2066  
Telephone: (619) 552-8400  
Facsimile: (213) 955-0440